With a significant increase in rabies exposures this year, Rodney Rohde, PhD, talks about seeking medical attention after animal interactions as well as clinical treatment when people have been bit or scratched.
|Videos|September 30, 2016
Prognosis of Babies with Zika-related Complications
Author(s)Contagion Editorial Staff
Pedro Fernando da Costa Vasconcelos, MD, PhD, director of WHO Collaborating Center for Arbovirus and Research, Evandro Chagas Institute, discusses the prognosis of babies with Zika-related complications.
Advertisement
Pedro Fernando da Costa Vasconcelos, MD, PhD, director of WHO Collaborating Center for Arbovirus and Research, Evandro Chagas Institute, discusses the prognosis of babies with Zika-related complications.
Interview Transcript (slightly modified for readability)
“In the babies that [are] born with microcephaly, other central nervous system malformations, and other extreme malformations, perhaps these babies will need life[-long] complete support, [with regards to] neurology, psychology, physical therapy, and other [complications], because [Zika] is most intense and severe when [babies are] born with this malformation.
Many of [these babies] die in a few minutes, few days, or few weeks after they’re born [with these Zika-related complications]. But those ones that survive will need assistance for [a] lifetime. Of course these babies [have other] immune system problems [because of] Zika virus infection. So they need assistance to fight against [some otherwise harmless] infections properly, [such as] pneumonia, severe diarrhea and other complications that can appear during Zika virus infection in [a] baby that is already born with microcephaly [or] other malformation. Probably the immune system is typically altered.”
Advertisement
Related to this article
UTI guidelines are moving away from complicated or uncomplicated infections to localized or systemic classification terminologies. Guidelines author Zachary Nelson, PharmD, MPH, BCIDP, provides further insights on the changes including applying antibiograms, potential costs, and whether clinicians will embrace these new classifications.
Demonstrating a diagnostic test works is no longer enough. Clinicians and laboratories also need evidence on how to adopt it in everyday practice. Andrea Prinzi, PhD, MPH, SM(ASCP), explains how implementation science can help infectious disease and clinical microbiology teams turn evidence into routine care.
Kenya reported its first imported Bundibugyo Ebola death as the Democratic Republic of Congo (DRC) outbreak surpassed 8,600 confirmed cases and 4,148 deaths, with 896 patients hospitalized in isolation. Here is a report on the latest numbers as well as vaccine and therapeutic study updates.
FDA-cleared single-step immunoblot tests built on recombinant antigens from multiple Borrelia species detected nearly twice as many early Lyme disease cases as standard 2-tier testing. Joseph J. Burrascano Jr, MD, offers insights into what the new tests mean for clinicians.
Lori Handy, MD, provides guidance in these areas, including presentation before rash onset, when patients should be considered for the inpatient setting, and what treatment looks like.
Jason Pogue, PharmD, BCPS, BCIDP, contextualizes preliminary data looking at this trial and other extended-spectrum beta-lactamase (ESBL) studies, which reopens the debate around carbapenem-sparing treatment options.
Following World Rabies Day and a CDC health advisory on a 17% rise in exposure-related calls, Rodney E. Rohde, PhD, explains what the increase means, what people should do when they have an animal bite or scratch, and how clinicians should assess risk and administer post-exposure prophylaxis (PEP).